



Response to “Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma”

Yae Won Park¹, Kyunghwa Han¹, Se Hoon Kim²

¹Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea

²Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea

Keywords: Cyclin-dependent kinase inhibitor; Glioma; Magnetic resonance imaging; Radiogenomics

We have carefully reviewed the Letter for our recent article by Takahashi et al. [1] with great interest. In short, the comments highlight the constraints of linear-based classifications such as logistic regressions (in strict terms, logistic regression uses a logistic function rather than a linear equation), which we employed in our study to predict CDKN2A/B homozygous deletion in IDH-mutant astrocytomas using qualitative and quantitative imaging

features. They further suggest the potential benefits of non-linear processing with deep learning, which could provide insights beyond what linear processing can offer. While we acknowledge the promising results of deep learning in neuro-oncology imaging, we would like this opportunity to discuss several limitations of deep learning, drawing from our own experience, and to explain why logistic regression is a better approach for our current study. Moreover, we would like to raise a question regarding the proportion of CDKN2A/B homozygous deletion in IDH-mutant astrocytomas, as presented in several articles.

First, when constructing a classification model with deep learning in a relatively small dataset without true external validation, there is a notable risk of overestimating the performance. Thus, the results should be interpreted with caution [1]. The use of a small training dataset may lead to overfitting of the model, particularly when dealing with complex deep learning models with various hyperparameters [2]. While cross-validation or split-sample validations are well-known internal validation methods commonly used for preliminary evaluation of model performance, they cannot replace external validation, which is crucial for verifying an overparameterized classification model [1,3]. In contrast, a logistic regression model, as an extension of the linear model, is less prone to overfitting and typically results in better generalizability [4]. Therefore, as our study has a data imbalance (only 13.6% of patients exhibit CDKN2A/B homozygous deletion among a total of 88 IDH-mutant astrocytoma patients) [5], logistic regression is a more suitable approach. Additionally, utilizing visual transformers may not be advisable in the context of comparatively rare tumor types in neuro-oncology. This is because visual transformers require a larger amount of data and high memory requirements, even much more than convolutional neural networks [6].

Another advantage of logistic regression is its interpretability, which aligns with the primary objective of our study to provide simple imaging information that will directly aid neuroradiologists in real-world practice. In cases where interpretability is crucial, logistic regression models yield straightforward and easily interpretable results, setting them apart from deep learning approaches [7], which is well-known for its “black box” nature, despite efforts to improve its interpretability or explainability [8,9].

Received: September 24, 2023 **Accepted:** September 25, 2023

Corresponding author: Se Hoon Kim, MD, PhD, Department of Pathology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea

• E-mail: paxco@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Furthermore, our imaging results, such as infiltrative pattern, maximal diameter, and higher cerebral blood volume, which indicate a higher probability of CDKN2A/B homozygous deletion in IDH-mutant astrocytomas, are simple and intuitive, and can be directly applied in clinical practice.

Third, multivariable logistic regression involves the assumption that all of the explanatory variables are independent of each other. In our study, we assessed the interrelation of imaging features, using variance inflation factor (VIF) to detect multicollinearity between the variables (all variables showed a VIF < 10 in our study) [5].

Lastly, the data imbalance of CDKN2A/B homozygous deletion in IDH-mutant astrocytomas is inevitable. The reported frequencies of CDKN2A/B homozygous deletions using various datasets range from 0%–12% in histological grade 2, 6%–20% in histological grade 3, and 16%–34% in histological grade 4 [10]. Moreover, the reported frequency of CDKN2A/B homozygous deletion in all IDH-mutant astrocytomas ranges from 11%–13.8% [11–13]. A recent systematic review of IDH-mutant gliomas reported a median incidence of CDKN2A/B homozygous deletion of 22% across studies [10]. In our study encompassing 88 IDH-mutant astrocytoma patients, only 13.6% of patients exhibited CDKN2A/B homozygous deletion [5]. Consistently, a recent pathology article utilized the Cancer Genome Atlas (TCGA) dataset, where 31 out of 224 IDH-mutant astrocytoma patients (13.8%) had CDKN2A/B homozygous deletion, which aligned with this reported frequency [11]. However, in the recent articles on radiomics and/or deep learning using the TCGA dataset, 111 out of 234 patients (47.4%) exhibited CDKN2A/B homozygous deletion among IDH-mutant astrocytomas [14,15]. In our view, this proportion appears considerably higher than other reports using the TCGA dataset. To validate this, we examined the Supplementary Data provided in these articles [14,15]. Unfortunately, we could not find any information on the CDKN2A/B homozygous deletion status in the mentioned TCGA dataset. Hence, we gently suggest the authors from the previous articles [14,15] to collaborate with other experts, such as neuropathologists or bioinformaticians, to present the detailed molecular information from the TCGA dataset.

Although we have experience in deep learning, we do not believe that deep learning can be a “silver bullet” to all of the questions encountered in neuro-oncology imaging. Logistic regression, despite its simplicity and conventional nature, remains a potent statistical tool with distinct advantages, especially in rare neuro-oncology tumors. Due

to the inevitable limitation of our study, that is, the small dataset as well as data imbalance, we consider our current results as a “work in progress”. We emphasize that future multicenter validation is mandatory to validate our findings. Finally, we would like to thank the reviewers for their interest and insightful comments on our article.

Conflicts of Interest

Kyunghwa Han, the Statistical Consultant of the *Korean Journal of Radiology*, was not involved in the editorial evaluation or decision to publish this article. All authors have declared no conflicts of interest.

Author Contributions

Conceptualization: all authors. Data curation: Yae Won Park. Formal analysis: Yae Won Park. Investigation: Yae Won Park. Methodology: Kyunghwa Han. Project administration: Yae Won Park. Resources: Se Hoon Kim. Software: Yae Won Park. Supervision: Se Hoon Kim. Validation: Yae Won Park. Visualization: Yae Won Park. Writing—original draft: all authors. Writing—review & editing: all authors.

ORCID IDs

Yae Won Park

<https://orcid.org/0000-0001-8907-5401>

Kyunghwa Han

<https://orcid.org/0000-0002-5687-7237>

Se Hoon Kim

<https://orcid.org/0000-0001-7516-7372>

Funding Statement

None

REFERENCES

1. Takahashi K, Usuzaki T, Inamori R. Medical statistics unlock the gateway to further research: using deep learning to predict CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. *Korean J Radiol* 2023;24:1303-1305
2. Park SH, Choi J, Byeon JS. Key principles of clinical validation, device approval, and insurance coverage decisions of artificial intelligence. *Korean J Radiol* 2021;22:442-453
3. van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. *BMC Med Res Methodol* 2014;14:137
4. An C, Park YW, Ahn SS, Han K, Kim H, Lee SK. Radiomics machine learning study with a small sample size: single random training-test set split may lead to unreliable results. *PLoS One*

- 2021;16:e0256152
5. Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, Van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol* 2019;110:12-22
 6. Park YW, Park KS, Park JE, Ahn SS, Park I, Kim HS, et al. Qualitative and quantitative magnetic resonance imaging phenotypes may predict CDKN2A/B homozygous deletion status in isocitrate dehydrogenase-mutant astrocytomas: a multicenter study. *Korean J Radiol* 2023;24:133-144
 7. Dosovitskiy A, Beyer L, Kolesnikov A, Weissenborn D, Zhai X, Unterthiner T, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv:2010.11929 [Preprint]. [posted Oct 22, 2020; revised Jun 3, 2021; cited Sep 24, 2023]. <https://arxiv.org/abs/2010.11929>
 8. Hastie T, Tibshirani R, Friedman JH, Friedman JH. *The elements of statistical learning: data mining, inference, and prediction*. New York: Springer, 2009:347-369
 9. Lundberg SM, Lee SI. *A unified approach to interpreting model predictions*. In: Guyon I, Von Luxburg U, Bengio S, Wallach H, Fergus R, Vishwanathan S, et al., eds. 31th Annual Conference on Neural Information Processing Systems (NIPS 2017): Proceedings of the 30th International Conference on Neural Information Processing Systems; 2017 Dec 4-9; Long beach, United States of America. 2017:4768-4777
 10. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. Grad-cam: visual explanations from deep networks via gradient-based localization. *Int J Comput Vis* 2020;128:336-359
 11. Lu VM, O'Connor KP, Shah AH, Eichberg DG, Luther EM, Komotar RJ, et al. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. *J Neurooncol* 2020;148:221-229
 12. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol* 2018;136:153-166
 13. Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. *Neuro Oncol* 2019;21:1519-1528
 14. Gao J, Liu Z, Pan H, Cao X, Kan Y, Wen Z, et al. Preoperative discrimination of CDKN2A/B homozygous deletion status in isocitrate dehydrogenase-mutant astrocytoma: a deep learning-based radiomics model using MRI. *J Magn Reson Imaging* 2023 Aug 9. [Epub]. <https://doi.org/10.1002/jmri.28945>
 15. Zhang L, Wang R, Gao J, Tang Y, Xu X, Kan Y, et al. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma. *Eur Radiol* 2023 Aug 8. [Epub]. <https://doi.org/10.1007/s00330-023-09944-y>